Tag: venetoclax-based therapy

Venetoclax-based Regimens in AML: The New Standard or a Temporary Fix? Abstract Acute myeloid leukemia (AML) remains a challenging hematologic malignancy, particularly among older adults and patients unfit for intensive chemotherapy. Over the past decade, treatment models have shifted with the advent of venetoclax, a selective BCL-2